• Dong Dang, Chao Jiang, and Ming-Rui Xie.
• Department of Oncology, Yulin Hospital of Traditional Chinese Medicine, Yulin.
• Medicine (Baltimore). 2020 Jun 19; 99 (25): e20454e20454.

BackgroundThe aim of this study is to examine the efficacy of weekly amrubicin (WA) for treating refractory or relapsed non-small cell lung cancer (RRNSCLC).MethodsThe literature search will be performed using the Cochrane Library, MEDLINE, EMBASE, CINAHL, PsycINFO, Scopus, Chinese Biomedical Literature Database, WANGFANG, VIP database, and China National Knowledge Infrastructure from inception onwards up to the March 1, 2020. No language limitation will be implemented. Randomized controlled trials that examined the efficacy and safety of WA for the treatment of RRNSCLC will be included. Literature selection, data extraction, and methodological quality assessment will be handled by 2 independent authors. We will invite a third author to disentangle any divergences between 2 authors. We will carry out statistical analysis using RevMan 5.3 software.ResultsThis study will summarize current evidence to assess the efficacy and safety of WA for the treatment of RRNSCLC.ConclusionsThe findings of this study will provide helpful evidence for the clinician, and will promote further studies, as well as clarify the direction of research on WA for the management of RRNSCLC.Study registration number: INPLASY202040168.

22 keywords...

hide…